Kymera Therapeutics to Participate in Upcoming September Conferences
Kymera Therapeutics (NASDAQ: KYMR) announced that its Co-Founder, President, and CEO, Nello Mainolfi, will participate in several upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kymera Therapeutics (NASDAQ: KYMR) announced that its Co-Founder, President, and CEO, Nello Mainolfi, will participate in several upcoming investor conferences. Key events include the 2022 Wells Fargo Healthcare Conference on September 7 at 1:20 p.m. ET, the Morgan Stanley 20th Annual Global Healthcare Conference on September 14 at 8:00 a.m. ET, and the 2022 Guggenheim Nantucket Therapeutics Conference on September 28 at 2:15 p.m. ET. Presentation webcasts will be accessible on Kymera's website, with archived replays available for 90 days.
Details
News Market Reaction – KYMR
The recorded move for KYMR in the trading session of this news was -9.02%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, announced that Nello Mainolfi, PhD, Co-Founder, President and CEO, will participate in Fireside Chats at the following upcoming investor conferences:
- 2022 Wells Fargo Healthcare Conference: September 7th at 1:20 p.m. ET
- Morgan Stanley 20th Annual Global Healthcare Conference: September 14th at 8:00 a.m. ET
- 2022 Guggenheim Nantucket Therapeutics Conference: September 28th at 2:15 p.m. ET
Presentation webcasts will be available under "Events and Presentations" in the Investors section of the Company's website at www.kymeratx.com. Archived webcast replays will be available on the website for approximately 90 days.
About Kymera Therapeutics
Kymera is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways inaccessible with conventional therapeutics. Kymera’s Pegasus platform is a powerful drug discovery engine, advancing novel small molecule therapies candidates designed to harness the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. With a focus on undrugged nodes in validated pathways, Kymera is advancing a pipeline of novel therapeutic candidates designed to address the most intractable of pathways and provide new treatments for patients. Kymera’s initial programs target IRAK4, IRAKIMiD, and STAT3 within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat patients with a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. For more information, visit www.kymeratx.com.
Investor Contact:
Bruce Jacobs
Chief Financial Officer
investors@kymeratx.com
857-285-5300
Chris Brinzey
Managing Director, Westwicke
chris.brinzey@westwicke.com
339-970-2843
Media Contact:
Todd Cooper
Senior Vice President, Corporate Affairs
media@kymeratx.com
857-285-5300
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.